Reuters
12 Aug 2026, 09:32 UTC · 1h ago
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
12 Aug 2026, 09:32 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Eli Lilly has filed six lawsuits against U.S. companies for illegally selling black-market versions of its experimental obesity drug retatrutide. — While protecting IP is positive, the existence of a black market for an unapproved drug highlights regulatory risks and potential safety liabilities for the company.
-0.20Which stocks this story touches
The company is taking proactive legal action to protect its intellectual property and prevent illegal sales of its experimental drug.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
4h ago
